Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have been newly diagnosed with mantle cell lymphoma confirmed by a tissue biopsy (histology).
- Your overall daily functioning is good (ECOG score 0–2, meaning you’re not very limited).
- You must be able to take pills by mouth (swallow tablets/capsules).
- You must enroll in the lenalidomide (Revlimid) REMS program and be willing to follow its rules, including pregnancy testing and birth control if relevant.
- You likely cannot have had chemotherapy for mantle cell lymphoma before (no prior MCL chemotherapy).
- You should not have serious recent neurologic or heart problems (including stroke or brain bleeding in the last 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests a combination of three targeted drugs (linperlisib, obinutuzumab, and venetoclax) for a rare, aggressive form of mantle cell lymphoma that has come back or not responded to prior treatments. The goal is to see if this drug combination can help shrink the cancer and improve outcomes.
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.